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Inﬂ  uenza infection in COPD
The importance of exacerbations in chronic obstructive pulmonary disease (COPD) is 
well recognized. There is much interest in the role of different viruses and bacteria 
in exacerbations, and the development of strategies against these pathogens. In this 
issue of the International Journal of COPD we have 3 reviews focused on the role of 
one particular pathogen; the inﬂ  uenza virus (Plans-Rubió 2007; Mallia and Johnston 
2007; Wesseling 2007). We are pleased to publish these state of the art reviews written 
by leading experts in the ﬁ  eld. These articles provide up to date opinions on different 
aspects of this virus in COPD, including virology, epidemiology, vaccination strate-
gies, and drug therapies. We have selected these reviews for publication based on 
clear synthesis of current data combined with expert opinion on the most important 
future issues.
The use of molecular diagnostic methods have enabled better quantiﬁ  cation of 
the role of inﬂ  uenza in causing COPD exacerbations. Studies using polymerase chain 
reaction for pathogen detection are presented in these reviews, and conﬁ  rm that inﬂ  u-
enza is one of the most common causes of viral exacerbations. Mallia and Johnston 
(2007) make the point that we do not fully understand the pathophysiological role 
of inﬂ  uenza in causing acute exacerbations, or the precise nature of virus–bacterial 
interactions during exacerbations. There is clearly a need for continued translational 
research that furthers our understanding of these basic pathophysiological mechanisms 
in humans.
The prevention and treatment of inﬂ  uenza in COPD is an important healthcare 
issue. While vaccination is generally recommended as a preventative measure, under-
utilization of this resource occurs in clinical practice. Plans-Rubió (2007) extensively 
reviews ways to increase vaccination uptake, providing an invaluable source of practi-
cal information regarding different implementation strategies. The role of amatidines 
and neuramidase drug therapies for COPD patients with inﬂ  uenza is reviewed in all 
3 articles, with data presented that supports their use to decrease the severity of infec-
tions. However, the authors raise important issues including cost-effectiveness and 
patient selection, highlighting the need for studies to deﬁ  ne the optimum strategies 
for the treatment of inﬂ  uenza infection in COPD patients.
We hope you ﬁ  nd these articles interesting and informative. It is our intention to 
continue to publish high quality review articles from leaders in all aspects of COPD 
ranging from molecular biology to clinical aspects.
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mode of standardization (Kullmann et al 2007) all can con-
tribute to limited reproducibility of results. It is extremely 
difﬁ  cult to address all potential methodological biases of 
ELISA when assessing EBC. Intra-assay variability is rela-
tively easy to assess: one can compare readings of duplicate 
or triplicate aliquots of the same samples. Determination 
of inter-assay differences again is best done from the same 
samples adding aliquots of it to two different plates of the 
assay. If results of inter-assay reproducibility are good, then 
different batches of the assay can be used to determine intra-
day or intra-week reproducibility. This potential difference 
needs to be taken into account when using EBC as a source 
of airway biomarkers (Huszar et al 2005). Determination of 
intra-week reproducibility then can be performed by 1) keep-
ing the ﬁ  rst sample for a week and measuring it together with 
the second (in this case however the potential effect of storing 
on mediator concentration needs to be taken into account); 
or 2) measuring the two samples by different batches of 
ELISA from the same manufacturer (in this case inter-assay 
variability complicates interpretation). Although it cannot be 
established from the study by Borrill and colleagues (2007) 
what kind of arrangement they used for the determination of 
intra-day and intra-week variability, their conclusion about 
the complexity of reproducibility holds very well.
Another issue their study touches upon is the limitations 
of the usefulness of biomarkers with limited reproducibility. 
Precise standardizations of traditional lung function tests 
and exhaled nitric oxide measurements were essential for 
these variables to provide accurate, well reproducible read-
ings and gain clinical acceptance. EBC biomarkers have to 
travel through the same path before they can become clini-
cally meaningful tools. The study by Borrill and colleagues 
(2007) adds important insight into the interpretation of 
observed differences of EBC LTB4 and 8-isoprostane and it 
also emphasizes the need for reproducibility data, not only 
in healthy subjects, but also in patients. COPD is a disease 
with ﬂ  uctuation of airway inﬂ  ammation and oxidative stress 
that only partially reﬂ  ected by clinical symptoms therefore 
it is reasonable to assume a lower than normal degree of 
reproducibility of biomarkers representing pathophysi-
ological events of the disease even under stable conditions. 
Therefore, long-term follow-up studies assessing biomarker 
reproducibility can help to better understand the dynamics of 
EBC biomarker proﬁ  le in this multiplex disease.
I hope you will ﬁ  nd the article by Borrill and colleagues 
(2007) stimulating from both clinical and research point of 
views.
Reproducibility of exhaled biomarkers 
in COPD—the road less traveled
Ildiko Horvath
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In recent years, interest in the measurement of exhaled 
biomarkers has increased, mainly driven by the unmet clini-
cal need to monitor airway inﬂ  ammation and the response 
to antiinﬂ  ammatory therapy. Beside exhaled nitric oxide 
measurement that entered clinical practice, measurement of 
biomarkers in exhaled breath condensate (EBC) is a rapidly 
expanding area of this ﬁ  eld. EBC is easy to collect as it only 
requires the noninvasive collection of exhaled breath in a 
cold trap. The obtained ﬂ  uid is a complex diluted solution 
of diverse biomarkers with various chemical stabilities. 
Due to the complexity of EBC and the fact that it is a much 
diluted sample, there are still several unsolved issues about 
standard protocols for measurements and there is a lack of 
reproducibility data for different biomarkers, particularly 
in disease states. The lack of knowledge and evidence on 
certain areas limited the ability of the European Respiratory 
Society/American Thoracic Society Task Force to make ﬁ  rm 
guidelines for each aspect of this sampling technique and 
prompted the authors to highlight areas for further research 
(Horvath et al 2005).
The current issue of the International Journal of COPD 
contains an important methodological contribution to this 
rapidly growing field (Borrill et al 2007). The authors 
performed a carefully designed study to assess within assay, 
within and between day reproducibility of EBC leukotriene B4 
(LTB4) and 8-isoprostane concentration measured by enzyme 
immunoassays (ELISA). They demonstrated that within 
assay variability was small, but there was a considerable 
within and between day variability for these biomarkers. 
Their two main conclusions derived from the study are: 
1) the cause of relatively low reproducibility of EBC LTB4 
and 8-isoprostane is multi-factorial including both biological 
and methodological variability; 2) the high level of variability 
they observed casts doubt on the current EBC methodology 
used to assess LTB4 and 8-isoprostane.
The very important contribution of this article to the ﬁ  eld 
is the careful analysis of reproducibility for two biomark-
ers. It has been shown for some EBC biomarkers that oral 
contamination during sampling (Gaber et al 2006; Marteus 
et al 2005), differences in collecting surfaces (Rosias et al 
2006), different assay techniques (Huszar et al 2005), and International Journal of COPD 2007:2(1)  3
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Active smoking among asthmatic 
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There is no doubt that tobacco smoking, whether active or 
passive, has a harmful effect on health of all individuals. 
Children are particularly vulnerable to environmental to-
bacco smoke (ETS), and if exposed have higher incidence 
of lower respiratory tract illnesses in their early years (Cook 
and Strachan 1999). Furthermore, it has been suggested 
that the high levels of ETS exposure during childhood may 
increase the risk of chronic obstructive respiratory disease 
in adulthood.
ETS exposure and asthma development
Numerous studies have demonstrated that children of tobacco 
smoking mothers have higher risk of developing asthma 
(Martinez et al 1992). Maternal smoking of more than 
10 cigarettes a day is associated with higher incidence of 
asthma, earlier onset of asthma symptoms, and an increased 
risk of using asthma medication compared with the children 
of nonsmoking mothers (Weitzman et al 1990). Other data 
suggest that maternal smoking prenatally and during the 
child’s ﬁ  rst year of life is a signiﬁ  cant risk factor for the 
development of wheeze in infancy, but not wheezing starting 
after the ﬁ  rst year of life (Murray et al 2004).
In utero tobacco smoke exposure may be more important 
than the post-natal exposure. Children born to mothers who 
have smoked in their pregnancies are more likely to have 
doctor-diagnosed asthma and current asthma requiring 
medication use (Gilliland et al 2001). This is an important 
public health issue, as the US national survey has shown 
that 16.5% of pregnant women smoke while expecting their 
babies (Ringel and Evans 2001). However, since the majority 
of mothers who smoke during pregnancy continue to smoke 
for the next few years (and children in the ﬁ  rst years of life 
generally spend the majority of their time in the mother’s 
care), it is often difﬁ  cult to distinguish what effects occur 
from in utero exposure and what effects are secondary to 
post-natal ETS exposure. The few studies that managed to 
carry out analyses which excluded the effect of postnatal ETS 
exposure showed a signiﬁ  cant association between smoking 
during the pregnancy and recurrent wheezing (Lannero 
et al 2006).
ETS exposure and asthma severity
Children with established asthma who are exposed to 
environmental tobacco smoke have more frequent acute 
exacerbations and poorer lung function (Oldigs et al 1991; 
Chilmonczyk et al 1993). There appears to be a dose-response 
relationship, with children both of whose parents smoke suf-
fering more than those where the mother alone smokes, with 
less respiratory symptoms in those children from families 
with no ETS exposure (Murray and Morrison 1993).
Active smoking and asthma in adolescence
Adolescence is the period when the majority of smokers 
start smoking. Active smoking during the childhood and 
adolescence seriously affects respiratory health by causing 
decreased lung growth, poorer lung function, increased spu-
tum production, airway obstruction, cough, and shortness of 
breath (Tyc and Throckmorton-Belzer 2006). A recent study 
conducted among teenagers has demonstrated that regular 
smoking in healthy nonallergic adolescents increases the 
risk of subsequent development of asthma (Gilliland et al 
2006). Active tobacco smoking induces lower airway inﬂ  am-
mation, and has been associated with diminished response to 
inhaled and systemic steroids in asthmatic patients.
Active smoking among adolescent asthmatics contributes 
to the frequency and severity of their asthma symptoms. This 
was conﬁ  rmed in a study by Mallol and colleagues (2007) 
in this issue, which presented the data on smoking habits of 
asthmatic adolescents in Chile. A further alarming ﬁ  nding 
of the study was the high prevalence of adolescent female 
smokers. This appears to mirror the ﬁ  ndings from many other 
countries, in which, even after massive media campaigns, International Journal of COPD 2007:2(1)  4
Editorial selection
cigarette smoking remains popular amongst teenagers, and 
particularly young women.
Why do adolescent asthmatics smoke?
Despite having a chronic respiratory disease, asthmatic ado-
lescents do not restrain themselves from smoking, but have 
equally high smoking rates as their peers, which raises the 
question of the possible factors that may predispose them to 
this form of addictive behavior (Zimlichman et al 2004; Jones 
et al 2006). Studies have indicated that adolescents who are 
nonadherent to their asthma treatment are more risk-taking 
and rebellious, therefore more prone to undertake health-
compromising behaviours (Tyc and Throckmorton-Belzer 
2006). Factors like exposure to smoking at home and having 
friends who smoke are likely to trigger smoking behavior 
in asthmatic adolescents. Children with chronic illness like 
asthma may also have both disease and treatment-related 
higher psychosocial distress. School absenteeism and separa-
tion from peers due to asthma morbidity may also contribute 
to smoking behavior by using smoking as a vehicle for recon-
necting with their peers. However, these factors can change 
depending on age, sex, race, and socioeconomic status (Tyc 
and Throckmorton-Belzer 2006).
How to reduce smoking among adolescents?
This topic has been the subject of a recent review article 
summarizing the current state of the art (Tonnesen 2002). 
There has been a huge number of high quality interventional 
studies conducted among teenagers using different school-
based programs targeting smoking behaviour (Thomas and 
Perera 2006). Although the majority of such trials have shown 
some beneﬁ  t on the prevention of active smoking in the short 
term, there is controversy about longevity of these effects. 
A study with the longest duration of intervention (lasting 
8 years) failed to demonstrate sustained effect of speciﬁ  c 
intervention (Thomas and Perera 2006).
Recently, governments and public health authorities have 
been trying to develop new policies which would reduce 
smoking. One of them has been an increase in cigarette 
taxes which proved to be effective among women of higher 
educational level (Ringel and Evans 2001).
Media advertisements have great inﬂ  uence on smoking 
behavior among young adults. Successful public health cam-
paigns to persuade governments of the need for legislation 
to end the tobacco advertising campaigns in media resulted 
in legislations banning all tobacco advertising in the UK 
(Tobacco Advertising and Promotion Act 2003) and many 
other developed countries. As a result of an EU Directive, 
there is a partial ban on tobacco advertising also exists 
throughout the EU.
However, developing countries largely lack such policies, 
and as a consequence, tobacco companies continue to market 
their products. In this era of globalization, the legislations 
to end the tobacco advertising needs to become global, and 
having smoke-free schools should be our common goal.
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